Orano Med

decorative

About Orano Med

Orano Med is an Orano subsidiary created in 2009 to develop innovative therapies to fight cancer.

decorative

Nuclear Medicine

Learn more about nuclear medicine and targeted alpha therapy (TAT) with lead-212, and about our ongoing research.

decorative

Pipeline

Orano Med is always looking for new opportunities to further expand its pipeline.

decorative

News & Materials

Read about the latest news and events, watch a video, or download our brochure.

decorative

Macrocyclics

Macrocyclics, an Orano Med company, is the global leader in chelating agent technologies for medicine.

Latest News

RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix(TM) for the treatment of neuroendocrine tumors

11/13/2018

RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix(TM) for the treatment of neuroendocrine tumors

Read more
Cellectar and Orano Med Announce Collaboration to Develop New Phospholipid Drug Conjugate

08/01/2018

Cellectar and Orano Med Announce Collaboration to Develop New Phospholipid Drug Conjugate

Read more
RadioMedix and AREVA Med announce initiation of Phase 1 clinical trial of AlphaMedix(TM), a Targeted Alpha Therapy for patients with neuroendocrine tumors

01/10/2018

RadioMedix and AREVA Med announce initiation of Phase 1 clinical trial of AlphaMedix(TM), a Targeted Alpha Therapy for patients with neuroendocrine tumors

Read more
Orano Med Video

Click here to view the latest Orano Med Video

Contact

For more information about Orano Med, please contact:
Alison Tise
Tel.: + 1 (301) 841-1673

Contact

For more information about Macrocyclics, please contact:

Garry Kiefer

Tel.: + 1 (469) 786-6060

CEO Cancer Gold Standard
decorative

Orano Med receives CEO Cancer Gold Standard accreditation

Twitter
decorative

Follow @OranoMed on

Linked In
decorative

Follow Orano Med on